FDA Sued by Consumer Group Over Alzheimer Drug Dosage

Higher doses of a drug sold by Eisai Co. Ltd. and Pfizer Inc. to treat Alzheimer’s disease should be halted because of potentially life-threatening side effects, a consumer group claimed in a lawsuit filed today in Washington.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.